Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Pre-EUA dossier for Cleveland Biolabs' entolimod submitted to FDA

June 16, 2015

Probuphine noninferior to sublingual buprenorphine in phase III trial in opioid dependence

June 9, 2015

AEOL-10150 doubles survival in primate model of radiation-induced lung injury

May 5, 2015

Adapt Pharma successfully completes pharmacokinetic study of intranasal naloxone

April 24, 2015

FDA approves filgrastim for myelosuppression in acute radiation injury

April 23, 2015

Tamoxifen found to inhibit the effects of amphetamine

April 21, 2015

Northeastern University patents CB1 receptor modulators

March 12, 2015

Substance abuse candidate GS-6637 well tolerated in healthy volunteers

March 10, 2015

Reversible change in enzyme's substrate specificity accelerates elimination of toxic acetaldehyde

Feb. 27, 2015

Cerecor acquires kappa opioid receptor antagonist from Eli Lilly

Feb. 23, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.